$2.58
▲ +0.8% Today
as of Sep 4, 16:47 ET
Last 30 days
Recent Press Releases & News
CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference
CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB)
CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)
Overview
52-week range
$2.13
$11
5% of range
Avg surprise (last 3)
-3.9%
Avg reaction (last 2)
-0.7%
50% positive
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Fri May 15, 2026 | Mar/2026 | $-0.86 | $-0.90 | +4.4% | -53.6% | -8.5% | earnings |
| Fri Aug 8, 2025 | Jun/2025 | $-0.70 | $-0.57 | -22.8% | — | — | earnings |
| Mon May 12, 2025 | Mar/2025 | $-0.56 | $-0.60 | +6.7% | — | +7.2% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.55 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.70 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | — | $322,569 | $2M | $2M | — | $2M |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-7M | $-8M | — | $-8M | $-7M | $-5M | — | $-5M |
| Net income | $-7M | $-8M | — | $-8M | $-6M | $-5M | — | $-5M |
| EPS (diluted) | — | — | — | — | — | — | — | $-0.55 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $22M | $8M | $8M | $9M | $8M | $11M | $9M | $8M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $26M | $15M | $23M | $31M | $38M | $39M | $43M | $49M |
| Total assets | $26M | $15M | $23M | $31M | $38M | $39M | $43M | $49M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $3M | $4M | $5M | $5M | $5M | $4M | $4M | $3M |
| Total equity | $23M | $11M | $18M | $26M | $33M | $35M | $39M | $46M |
Implied volatility — last 90 days
No IV snapshots yet for CRVO.
IV is captured twice daily (9:15 AM & 4:30 PM ET) for tickers with upcoming earnings. Comes online automatically once the next options refresh runs.